Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study

Background: Real-life data on the administration of letermovir as cytomegalovirus (CMV) primary prophylaxis after allogeneic hematopoietic cell transplantation (HCT) remain limited. Methods: We conducted a retrospective single-center matched cohort study, comparing consecutive high-risk allogeneic H...

Descripción completa

Detalles Bibliográficos
Autores principales: Royston, Léna, Royston, Eva, Masouridi-Levrat, Stavroula, Vernaz, Nathalie, Chalandon, Yves, Van Delden, Christian, Neofytos, Dionysios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069238/
https://www.ncbi.nlm.nih.gov/pubmed/33921218
http://dx.doi.org/10.3390/vaccines9040372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069238/
https://www.ncbi.nlm.nih.gov/pubmed/33921218
http://dx.doi.org/10.3390/vaccines9040372

Ejemplares similares